HS
Highly rated in
1
conditions
Highly rated in
1
conditions
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Heiko M. Schoder's experience treating your condition:
About Dr. Heiko M. Schoder

Heiko Schoder is a Nuclear Medicine expert in New York, New York. Schoder has been practicing medicine for over 24 years and is highly rated in 1 condition, according to our data. His top areas of expertise are Classical Hodgkin Lymphoma, T-Cell Lymphoma, Osteopenia, Tissue Biopsy, and Orchiectomy. He is licensed to treat patients in New York. Schoder is currently accepting new patients.

His clinical research consists of co-authoring 220 peer reviewed articles and participating in 15 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Heiko M. Schoder it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Heiko M. Schoder accepts the following insurance:

  •  Ambetter
Locations
1275 York Ave, New York, NY 10021
Background & Education
Graduate Institution
Other, 1998
Specialties
Nuclear Medicine
Licenses
Nuclear Medicine in NY
Hospital Affiliations
Memorial Sloan Kettering Cancer Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study
Serial PSMA PET Imaging in the Assessment of Treatment Response in Patients With Progressive Prostate Cancer
A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas
18F-FAC PET Imaging to Quantify Gemcitabine Tumor Drug Uptake and Biodistribution in Pancreatic Cancer Patients
Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging
The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules
Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images
PSMA PET Imaging of Recurrent Prostate Cancer
The Use of Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung and Liver Lesions and Assessment of Tumor Glycolysis
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Pilot Study Investigating the Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer
An Initial Study of FDG-PET/CT and MRI to Assess Thymic Function
Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy
Safety, Biodistribution and Radiation Dosimetry of [18F]PARPi
View 10 Less Clinical Trials -

220 Total Publications



Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors